Nemolizumab治疗6-12岁中重度瘙痒特应性皮炎患儿的III期研究
这项III期随机双盲安慰剂对照多中心研究纳入89例6-12岁特应性皮炎伴中重度瘙痒患儿,评估nemolizumab 30 mg每4周一次联合外用制剂的有效性与安全性。第16周5级瘙痒评分较基线变化nemolizumab组为-1.3,安慰剂组为-0.5,最小二乘均值差-0.8(95%CI -1.1至-0.5;P<0.0001),自给药第2天起即观察到改善,安全性特征与≥13岁患者相当。
要点
- 第16周5级瘙痒评分变化nemolizumab组-1.3 vs 安慰剂组-0.5,差异有统计学意义。
- nemolizumab组自给药第2天起即观察到瘙痒改善。
- 无不良事件导致停药,6-12岁安全性特征与≥13岁患者相当。
核心结论
- Nemolizumab可能成为外用制剂和抗组胺药未能充分改善瘙痒的儿童特应性皮炎患者的新治疗选择。
研究设计与样本
- 随机、安慰剂对照、双盲、平行组、多中心、16周III期研究,纳入89例6-12岁确诊特应性皮炎且外用制剂和口服抗组胺药后瘙痒反应不足的日本患儿。
- 患者按1:1随机接受nemolizumab 30 mg(n=45)或安慰剂(n=44)每4周一次(Q4W),全部完成研究。
- 患者平均年龄9.1岁(SD 1.9),平均特应性皮炎病程8.5年(SD 2.7)。
主要发现
- 第16周每周平均5级瘙痒评分较基线变化:nemolizumab组-1.3 vs 安慰剂组-0.5(最小二乘均值差-0.8,95%CI -1.1至-0.5;P<0.0001)。
- nemolizumab组自给药第2天起即观察到瘙痒改善。
- 次要终点结果支持nemolizumab。
- 无不良事件导致停药,6-12岁患者总体安全性特征与≥13岁特应性皮炎患者相当。
关键数值与推荐
- 主要疗效终点为第16周每周平均5级瘙痒评分较基线的变化。
- 次要疗效终点涉及瘙痒、特应性皮炎指标和生活质量。
- 安全性通过不良事件和实验室检查结果评估。
临床怎么用
- 对于6-12岁特应性皮炎伴中重度瘙痒、外用制剂和口服抗组胺药后瘙痒控制不佳的患儿,nemolizumab 30 mg每4周一次联合外用制剂可能改善瘙痒。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atopic dermatitis (AD) is a chronic, inflammatory skin condition affecting up to one-quarter of children. Uncontrolled pruritus associated with childhood AD, and the accompanying scratching, negatively impacts quality of life (QoL), sleep and development. The humanized monoclonal antibody nemolizumab, used concomitantly with topical agents, was shown to reduce pruritus and improve QoL in patients with AD aged ≥ 13 years. However, data relating to its efficacy and safety in younger children (aged < 13 years) have been lacking. OBJECTIVES: To evaluate the efficacy and safety of nemolizumab, administered concomitantly with topical agents, in Japanese paediatric patients (aged 6-12 years) with AD and inadequately controlled moderate-to-severe pruritus. METHODS: This was a randomized, placebo-controlled, double-blind, parallel-group, multicentre, 16-week, phase III study. Patients aged ≥ 6 and < 13 years, with confirmed AD, and an inadequate pruritic response despite treatment with topical agents and oral antihistamines were randomly assigned (1 : 1) to receive nemolizumab 30 mg or placebo every 4 weeks (Q4W). The primary efficacy endpoint was the change in the weekly mean 5-level itch score from baseline to week 16; secondary efficacy endpoints were related to pruritus, indicators for AD and QoL. Safety was assessed via adverse events (AEs) and laboratory test results. RESULTS: In total, 89 patients were enrolled, received either nemolizumab 30 mg (n = 45) or placebo (n = 44) Q4W, and completed the study. The mean patient age was 9.1 (SD 1.9) years, and mean duration of AD was 8.5 (2.7) years. The change in 5-level itch score from baseline to week 16 showed a statistically significant difference in the nemolizumab treatment group (-1.3) compared with placebo (-0.5; least-squares mean difference -0.8, 95% confidence interval -1.1 to -0.5; P < 0.0001). Improvements with nemolizumab were observed from the second day of administration. Secondary endpoints were in favour of nemolizumab. No AEs resulted in discontinuation, and the overall safety profile in patients aged 6-12 years was comparable with that in older patients (aged ≥ 13 years) with AD. CONCLUSIONS: Nemolizumab is a potential new treatment option for paediatric patients with AD whose pruritus has not been sufficiently improved with topical treatments and antihistamines.
引用
- Igarashi A, Katsunuma T, Matsumura T, et al. Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study. Br J Dermatol. 2023. PMID: 37522351. doi:10.1093/bjd/ljad268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。